Sitemap | Contact Us  

Welcome To Taj Pharmaceuticals Ltd API      

About Worldwide  |     FAQs    |    Careers     | |        Media Center  |  |    Taj Pharmaceuticals  World   | |     TAJ Group 

       2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved

active Pharma research lab Taj Pharma  API

      India              Latin America/ Caribbean            Africa & Middle East              Asia              Russia              Europe  
Sodium Valproate Manufacturers in India Suppliers Sodium Valproate Exporters Distributors Sodium Valproate api active pharmaceuticals ingredients Sodium Valproate manufacturers Side Effects bulk drugs raw material Sodium Valproate companies Side Effects Importers Sodium Valproate Sodium Valproate Exporters Sodium Valproate exporters FDA Sodium Valproate DMF Symptoms Generic Taj Pharmaceuticals Ltd. active pharmaceutical ingredients suppliers pharmaceutical Sodium Valproate manufacturing pharmaceutical drugs pharmaceutical intermediates Sodium Valproate pharmaceutical chemicals pharmaceutical raw materials Sodium Valproate active pharmaceutical ingredients Sodium Valproate committee active pharmaceutical ingredients manufacturer Sodium Valproate Active Pharmaceutical Ingredients manufacturer Sodium Valproate exporter drug ingredients pharmaceuticals Pharmaceuticals API Manufacturer Sodium Valproate, Sodium Valproate manufacturer India, Sodium Valproate product, Sodium Valproate products, Api preparation, Certificate of Analysis API manufacturer product, Sodium Valproate anti ulcer product, Certificate of Origin COA Sodium Valproate COS Sodium Valproate, pharmaceutical generic, pharmaceutical drug, medical, Sodium Valproate pharma healthcare, pharma patents, contract MSDS manufacturing Trader Sodium Valproate pharma, generic pharma, HCL pharma MSDS pharmaceutical products, pharmaceutical formulations, generic import API, Sodium Valproate expectorant Pharmaceutical GMP Method of analysis formulations manufacturer, Sodium Valproate DMF drug master file pharmaceutical Anti Cancer active ingredient exporter from India, pharma Sodium Valproate ingredients, api, HIV Sodium Valproate, tablets, capsules, syrup & protein Sodium Valproate powder, GMP of Plant api nutraceuticals, gynec products, ortho ingredients in India, oncology products, Sodium Valproate gastroenterology products, buy, sell orthopaedic product, who gmp, cGMP, US FDA, Sodium Valproate WHO, UKMHRA Approval
   API >>>
   Pharmaceuticals API List
   Product Development
   Product Search
   Agro Chemicals
   Custom Pharma Services
   Contact Us

sodium valporate tablets



























HOME >> API >> API List 3 >> Sodium Valproate

Sodium Valproate CAS number 1069-66-5

Sodium Valproate CAS number 1069-66-5

Molecular Structure

Sodium Valproate  Formula C8H15NaO2

Sodium Valproate
pdf api

CAS number 1069-66-5

Formula C8H15NaO2
Molecular Weight 166.19
ATC code N03AG01
PubChem 14047
ChemSpider 13428
Chemical data

Mol. mass 166.20 g/mol
Pharmacokinetic data
Bioavailability ?
Protein binding 9095%
Metabolism 75% by CYP enzymes
Half life 918 hours
Excretion 20% excreted as glucuronide

  • CAS number 1069-66-5
  • Formula C8H15NaO2
  • Molecular Weight 166.19
  • ATC code N03AG01
  • Pub Chem 14047
  • Chem Spider 13428

Microbiological Test
Total plate count MAX 1000/g
Yeast&mold MAX 100/g
E.Coli Negative 

IUPAC Name: sodium 2-propylpentanoate | CAS Registry Number: 1069-66-5
Synonyms: Sodium valproate, Valproate sodium, Depakene, Epilim, Convulex, Eurekene, Labazene, Orfiril, Valerin, Natrium valproat, Selenica, Sodium 2-propylpentanoate, Valproic acid sodium salt, Dipropylacetate sodium, Sodium dipropylacetate, Depakene (TN), Selenica (TN), Sodium bispropylacetate, Valproic acid sodium, Valproinsaeure, natrium

Molecular Formula: C8H15NaO2 Molecular Weight: 166.193270 [g/mol]
H-Bond Donor: 0 H-Bond Acceptor: 2
Sodium valproate is indicated mainly for complex or pure absence seizure, it can also be kinds to treat myoclonia or assist to treat it. Which is white powder, slightly subastringent, soluble to water.

Sodium valproate (INN) or valproate sodium (USAN) is the sodium salt of Valproic acid and is an anticonvulsantanticonvulsant used in the treatment of epilepsy and bipolar disorder, as well as other psychiatric conditions requiring the administration of a mood stabilizer. The intravenous formulations are used when oral administration is not possible.

  • MF: C8H15NaO2
  • MW: 166.20 g/mol
  • Metabolism75% by CYP enzymes
  • Half life9-18 hours
  • Excretion: 20% excreted as glucuronide


  • Sodium valproate is the widely used an anti-epileptic drug in the pediatric population. Nausea, vomiting, anorexia, amenorrhoea, sedation, tremor, weight gain, alopecia, and hepato-toxicity are the most common side effects of this drug.The hepatotoxicity may manifest in several ways: transient elevation of transaminase values, reversible hyperammonemia with liver disease, or Reye syndrome - like syndrome, or progressive hepatitis.

  • Patients with epilepsy who are on sodium valproate have been reported to have low serum carnitine levels and this secondary carnitine deficiency has been reported in the literature. Prolonged treatment with sodium valproate more than other anticonvulsantsanticonvulsants, enhances renal losses of carnitine esters, lowers serum carnitine levels, and results in secondary carnitine deficiency.It also may cause a decrease in serum free carnitine levels by inhibition of plasmalemmal carnitine uptake.


This compound has been obtained by two different ways:

  • The reaction of dipropylcarbinoldipropylcarbinol with HBr gives 4-bromoheptane, which is treated with KCN to yield 2-propylpentanenitrilepropylpentanenitrile .Finally, this compound is hydrolyzed to the target compound with NaOH or with H2SO4.
  • The condensation of cyanacetic acid ethyl ester with propyl bromide by means of sodium propoxide in propanol gives crude dipropylcyanaaceticdipropylcyanaacetic acid ethyl ester, which, without isolation, is hydrolyzed with NaOH in hot water yielding dipropylcyanaceticdipropylcyanacetic acid .The decarboxylationdecarboxylation of dipropylcyanaceticdipropylcyanacetic acid at 140-

Safety Profile

All antiepilepic medications have been shown to be associated with higher risks of fetal abnormalities (mostly for spina bifida) since at least 1983 with the risks being related to the strength of medication used and use of more than one drug.Valproate has also been recognised as sometimes causing a specific facial changes ("facial phenotype") termed "fetal valproate syndrome".Sodium valproate has been associated with the rare condition paroxysmal tonic upgaze of childhood, also known as Ouvrier-Billson syndrome, from childhood or fetal exposure (this condition resolved after discontinuing valproate therapy)

Mechanism Of Toxic Effects

Valproate is a drug with anticonvulsant activity against a wide range of seizure types and appears to be well tolerated at therapeutic doses. In therapeutic use valproate's action may be related to altered turnover of GABA and actions on voltage sensitive sodium channels. The mechanisms involved in toxicity are unclear. It appears to have teratogenic effects in therapeutic doses.

Information Associated with Product:
Detail icon
Product Enquiry Product Quotation Sample Request Place Your Order  
Product Enquiry Product Quotation Sample Request Place Your Order  

Taj Pharmaceuticals API Logo

Sodium Valproate

Api Manufacturer,Export,Supplies,Manufacturing in India

Copyright Taj Pharmaceuticals Ltd. | Privacy Policy | Terms & Conditions | Sitemap


    Investor Relations    Feedback     Contact Worldwide    Sitemap


taj group logo
2004 - 2009 Taj Pharmaceuticals Limited . All rights reserved
Note:-We are committed to helping you find the right answers to your questions and concerns. However, this web site is not intended to give investment advice, promote the use of Taj Pharmaceuticals Limited  products or provide information on which to base medical treatment. If you have questions regarding any Taj Pharmaceuticals Ltd product or are experiencing a medical emergency, please consult your health care provider.
Additionally, contact information on this web site cannot be used to report adverse drug events. If you are a physician, please follow the procedures required by your country's regulations. Please choose one of the given options to contact us and we will respond to your inquiry as quickly as possible.